Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6843093 | 0.85 | GAA (0.52) | GAAALDH1A1CYP3A4SMN1; SMN2TDP1 | |
| SCHEMBL7081820 | 0.83 | ADRA2B (0.56) | FFAR4GAAALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL4548140 | 0.80 | LMNA (0.69) | GAAALDH1A1MEN1POLBKMT2A | |
| SCHEMBL18292531 | 0.70 | GAA (0.71) | FFAR4GAAALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL12903578 | 0.70 | SMN1; SMN2 (0.76) | GAAALDH1A1CYP3A4SMN1; SMN2TDP1 | |
| SCHEMBL7587082 | 0.69 | FFAR4 (0.71) | FFAR4SMN1; SMN2RORCTP53 | |
| SCHEMBL27228854 | 0.69 | MEN1 (0.60) | FFAR4RORCMEN1POLBKMT2A | |
| SCHEMBL19399664 | 0.68 | GAA (0.68) | GAAALDH1A1CYP3A4SMN1; SMN2TDP1 | |
| SCHEMBL7081755 | 0.68 | ADRA2B (0.60) | GAAALDH1A1CYP3A4SMN1; SMN2TDP1 | |
| Sulfamethazine SCHEMBL151305 | 0.67 | ALDH1A1 (1.00) | GAAALDH1A1CYP3A4SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6767909-B2 | CARDIOVASCULAR DISORDERS; VASOCONSTRICTION | OY JUVANTIA PHARMA LTD. (FI) | 2004-07-27 | — | — | US | disclosed |
| US-20030073710-A1 | Compounds useful for treatment or prevention of disease mediated by alpha-2B-adrenoceptor | OY JUVANTIA PHARMA LTD (FI) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073710-A1 | Compounds useful for treatment or prevention of disease mediated by alpha-2B-adrenoceptor | ADRB2, ADRB3, ADRB1 | PTGDR2 1843/4885FFAR4 939/4885CNR2 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.